Oxford researchers have unveiled a photodynamic composition, branded ‘Sunshine Against Cancer’, which they claim marks a significant breakthrough in the field.
The team from Oxperial BioHealth introduced Green Products Photodynamic Therapy (GPDT) at the 2024 Pharmaceutical Science Conference in Barcelona and the 20th Guangzhou International Symposium on Molecular Medicine.
Led by Dr. Daniel T. H. Chen, Dr. Ta-Chun Liu, Pharmacist Shin-Yi Huang, and Dr. Yao-Kuan Chen, the team demonstrated that GPDT—a pure, plant-based composition—induces apoptosis (programmed cell death) in human cancer cells, a process significantly enhanced by sunlight exposure.
The therapy harnesses the therapeutic properties of plant chlorophyll and other natural compounds, offering a sustainable, non-invasive alternative to conventional methods.
The team’s work has already secured patents in the UK and Taiwan, with multi-national patent protections currently underway. GPDT’s ability to inhibit tumour cell growth and differentiation positions it as a groundbreaking development in oncology. This eco-friendly and innovative approach integrates photodynamic activation with natural ingredients, positioning it as a novel tool in global cancer research and care.
The international medical and pharmaceutical communities have shown interest in this breakthrough, positioning GPDT as a potential game-changer in the fight against one of humanity’s most challenging diseases. Could sunlight hold the key to a brighter, cancer-free future? The answer may be closer than ever.
Cancer continues to be the leading cause of death globally, but a groundbreaking innovation could change the game. At the 2024 Barcelona Global Pharmacology Symposium, Dr. Daniel T. H. Chen from Oxford University presented their findings on GPDT (Green Products Photodynamic Therapy), a revolutionary photokinetic preparation that leverages sunlight and natural plant compounds to target cancer cells at the cellular level.
GPDT utilises the 400nm-700nm wavelength range of sunlight to activate natural plant components, generating reactive oxygen species, including single-state oxygen molecules, which have demonstrated cancer cell inhibitory effects in laboratory studies. This approach is positioned as a non-invasive and complementary wellness option for those seeking alternatives to traditional methods often associated with significant side effects.
“GPDT is the world’s first natural photokinetic solution, combining sunlight and botanicals to offer a gentler option for maintaining cellular balance and supporting overall health. By integrating outdoor sunlight exposure and plant-based dietary elements, individuals can pursue a more natural, holistic path to wellness,” explained Dr. Daniel Chen.
The team believes that, with its eco-friendly foundation and innovative integration of natural elements, GPDT is poised to contribute to a new era of health management—where the synergy of sunlight and nature takes centre stage.
Oxperial BioHealth has announced plans to debut PropoLight, the world’s first GPDT (Green Products Photodynamic Therapy) product, in the first half of 2025. Marketed as a premium health supplement, PropoLight is designed to support overall wellness, particularly for individuals seeking additional measures to maintain cellular health.
Next steps for PropoLight involve obtaining further certifications and rigorous trials in the UK and US, with the aim of establishing the groundwork for introducing a pharmaceutical-grade version of the product to the global market.